Single inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis

Simple item page
dc.contributor.authorRodriguez-Martinez, Carlos E.
dc.contributor.authorSossa-Briceno, Monica P.
dc.contributor.authorCastro-Rodriguez, Jose A.
dc.date.accessioned2025-01-20T16:07:39Z
dc.date.available2025-01-20T16:07:39Z
dc.date.issued2024
dc.description.abstractObjectiveThe aim of the present study was to determine the cost-utility of single inhaler combination inhaled corticosteroid and a long-acting beta 2-agonist (ICS/LABAs) as both maintenance and reliever (SMART) compared with a step-up maintenance treatment with a fixed medium to high dose of ICS combined with LABA and a short-acting beta 2-agonist (SABA) as reliever (ICS-LABA maintenance plus SABA) among patients aged 12 years or more with poorly controlled asthma in Colombia.MethodsA Markov-type model was developed to estimate the costs and health outcomes of a simulated cohort of patients aged 12 years or more with uncontrolled asthma treated for 12 months. The main effectiveness data were obtained from a recent meta-analysis. The main outcome was the variable ''quality-adjusted life-years'' (QALYs).ResultsThe base-case analysis showed that the budesonide/formoterol (BUD/FORM) SMART strategy was associated with lower overall treatment costs (US $3,062.37 vs. $4,462.02 average cost per patient over 12 months) and the greatest gain in QALYs (0.8511 vs. 0.8258 QALYs on average per patient over 12 months) compared with ICS-LABA maintenance plus SABA at step 4, thus leading to dominance.ConclusionsIn patients aged 12 years or more with uncontrolled asthma at GINA step 3 or 4, the BUD/FORM SMART strategy at either step 3 or 4 is cost-effective compared with the ICS-LABA maintenance plus SABA at step 4 strategy, because it shows a greater gain in QALYs at lower total treatment costs.
dc.fuente.origenWOS
dc.identifier.doi10.1080/02770903.2024.2410424
dc.identifier.eissn1532-4303
dc.identifier.issn0277-0903
dc.identifier.urihttps://doi.org/10.1080/02770903.2024.2410424
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/90012
dc.identifier.wosidWOS:001324100200001
dc.language.isoen
dc.revistaJournal of asthma
dc.rightsacceso restringido
dc.subjectCombination of corticosteroid and long-acting beta 2 agonists
dc.subjectcost-effectiveness
dc.subjectpersistent asthma
dc.subjectquality-adjusted life-years
dc.subjectsingle inhaler
dc.subjectseparate inhalers
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleSingle inhaler combination inhaled corticosteroid-formoterol as both maintenance and reliever (SMART) compared with a step up of treatment with fixed-dose inhaled corticosteroid-long-acting β2-agonist maintenance with a short-acting β2-agonist as reliever in adolescents and adults with poorly controlled asthma in Colombia: a cost-utility analysis
dc.typeartículo
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas